Artificial intelligence is starting to transition from being software to becoming a means of scientific discovery, and the latter development did not go unnoticed in the biotech market sector last week. Shares of CRISPR Therapeutics (CRSP) fell after Anthropic revealed that its Claude AI model had independently discovered a new uncharacterized enzyme system that shows certain similarities to CRISPR.
Anthropic stated that Claude independently analyzed an extensive database of DNA sequences and discovered what it called array-associated reverse transcriptases, or ARTs. Notably, scientists still do not know what the primary function of the system is. Anthropic stated that further experiments are being carried out.